abstract |
The present invention relates to polypeptides comprising a CD4 binding moiety, a gp41 binding moiety, an HIV fusion peptide inhibitor moiety, and combinations thereof. More specifically, the present invention relates to a polypeptide comprising a fibronectin-based skeletal domain protein that binds to CD4, a fibronectin-based skeletal domain protein that binds to the N17 domain of gp41, and an HIV fusion peptide inhibitor or a combination thereof. The invention also relates to the use of breakthrough proteins in therapeutic applications for the treatment of HIV. |